TrialPloS one2011

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

Clare F Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.